Updated Long-Term Follow-Up From the Phase 1b BOT+BAL Study at ESMO GI 2026 – Agenus
oncodaily - Agenus shared a post on LinkedIn: “At ESMOGI26, Agenus will share updated long-term follow-up from the Phase 1b study evaluating botensilimab plus balstilimab (BOT+BAL) in patients with MSS metastatic colorectal […]
AI Summary: Updated follow‑up data presented for botensilimab plus balstilimab reveal meaningful and durable activity in microsatellite‑stable metastatic colorectal cancer, with especially encouraging outcomes in patients lacking active liver metastases. The Agenus combination, showcased at a major gastrointestinal oncology meeting, renews interest in immune strategies for historically refractory MSS disease.
- Agenus releases Phase 1b three-year BOT+BAL survival data (2)
- Clinical and community reaction: experts weigh in on BOT+BAL (3)
- ESMO GI: BOT+BAL benefits in patients without active liver metastases (3)
- All Other Stories
Agenus releases Phase 1b three-year BOT+BAL survival data
Clinical and community reaction: experts weigh in on BOT+BAL
ESMO GI: BOT+BAL benefits in patients without active liver metastases
All Other Stories
Related Stories
Merck and Moderna report positive phase‑3 melanoma vaccine results / 10 days
Belzutifan plus lenvatinib outperforms cabozantinib in advanced RCC / 11 days
First patient enrolled in AACR-ADOPT-GEA gastroesophageal cancer trial / 22 days
Phase 1 trial shows cevostamab activity in relapsed multiple myeloma / 5 wks
EMERALD‑3 tests tremelimumab/durvalumab combos for embolisation‑eligible HCC / 1 month
Zanidatamab improves PFS over trastuzumab in HER2 GEA / 2 months
MAGE‑A4/A8 TCR bispecific T‑cell engager shows activity in solid tumors / 2 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Research Funding, Hearing Loss, Venture Capital, Long COVID and look for the RSS link.
StackHealth Time Machine